Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease

Author： Montoro-García Silvia   Shantsila Eduard   Lip Gregory YH  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.18, Iss.1, 2014-01, pp. : 43-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate® P/Humate-P®): In von Willebrand Disease and Haemophilia A

By Carter Natalie J.   Scott Lesley J.  

Drugs, Vol. 67, Iss. 10, 2007-01 ,pp. : 1513-1519

Adis International

Access to resources Recommend Favorite

Von Willebrand disease

By Wilde Jonathan T  

Clinical Medicine, Vol. 7, Iss. 6, 2007-12 ,pp. : 629-632

Royal College Of Physicians

Access to resources Recommend Favorite

Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate® P/Humate-P®) in von Willebrand Disease and Haemophilia A: A Viewpoint by Eric Berntorp

By Berntorp Eric  

Drugs, Vol. 67, Iss. 10, 2007-01 ,pp. : 1520-1520

Adis International

Access to resources Recommend Favorite

High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 13, 2010-05 ,pp. : 1480-1493

Bentham Science Publishers

Access to resources Recommend Favorite

Thrombospondin-1 in Von Willebrand Factor Function

By  

Current Drug Targets, Vol. 9, Iss. 10, 2008-10 ,pp. : 822-832

Bentham Science Publishers

Access to resources Recommend Favorite